| 12421197 |
Aminopyrazine derivatives as PI3K-γ inhibitors |
Brent Douty, Yanran Ai, David M. Burns, Andrew P. Combs, Nikoo Falahatpisheh +6 more |
2025-09-23 |
|
| 12365668 |
Aminopyrazine diol compounds as PI3K-y inhibitors |
Andrew P. Combs, Nikoo Falahatpisheh, Lixin Shao |
2025-07-22 |
|
| 12030885 |
Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors |
Andrew W. Buesking, Richard B. Sparks, Andrew P. Combs, Brent Douty, Nikoo Falahatpisheh +5 more |
2024-07-09 |
$15,981,000 |
| 12006320 |
Heterocyclic derivatives as PI3K inhibitors |
Yanran Ai, Andrew P. Combs, Nikoo Falahatpisheh, Lixin Shao, Artem Shvartsbart |
2024-06-11 |
$44,848,000 |
| 11958861 |
Spirocyclic lactams as JAK2 V617F inhibitors |
Charles Cole, Nikoo Falahatpisheh, Kai Liu, Lixin Shao, Darius Vrubliauskas +3 more |
2024-04-16 |
$36,460,000 |
| 11952367 |
Pyridine and pyridimine compounds as PI3K-gamma inhibitors |
Richard B. Sparks, Andrew P. Combs, Andrew W. Buesking, Lixin Shao, Haisheng Wang +1 more |
2024-04-09 |
$75,635,000 |
| 11926616 |
Aminopyrazine diol compounds as PI3K-γ inhibitors |
Andrew P. Combs, Nikoo Falahatpisheh, Lixin Shao |
2024-03-12 |
$38,520,000 |
| 11926630 |
Tertiary alcohols as PI3K-γ inhibitors |
Brent Douty, Andrew W. Buesking, David M. Burns, Andrew P. Combs, Nikoo Falahatpisheh +7 more |
2024-03-12 |
$38,520,000 |
| 11773102 |
Heterocyclic compounds as PI3K-γ inhibitors |
Artem Shvartsbart, Andrew P. Combs, Lixin Shao, Nikoo Falahatpisheh, Ge Zou +4 more |
2023-10-03 |
$78,215,000 |
| 11744832 |
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
James D. Rodgers |
2023-09-05 |
$81,517,000 |
| 11691971 |
Naphthyridinone compounds as JAK2 V617F inhibitors |
Lixin Shao, Liangxing Wu, Wenqing Yao |
2023-07-04 |
|
| 11396502 |
Substituted heterocyclic derivatives as PI3K inhibitors |
Andrew P. Combs |
2022-07-26 |
$108,731,000 |
| 11352340 |
Pyridine and pyridimine compounds as PI3K-gamma inhibitors |
Richard B. Sparks, Andrew P. Combs, Andrew W. Buesking, Lixin Shao, Haisheng Wang +1 more |
2022-06-07 |
$111,176,000 |
| 11331320 |
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
James D. Rodgers |
2022-05-17 |
|
| 11306079 |
3-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as PI3K-gamma kinase inhibitors |
Artem Shvartsbart, Andrew P. Combs, Nikoo Falahatpisheh, Padmaja Polam, Lixin Shao |
2022-04-19 |
$53,989,000 |
| 11225486 |
Tertiary alcohols as PI3K-γ inhibitors |
Brent Douty, Andrew W. Buesking, David M. Burns, Andrew P. Combs, Nikoo Falahatpisheh +7 more |
2022-01-18 |
$120,701,000 |
| 11161838 |
Heterocyclic derivatives as PI3K inhibitors |
Yanran Ai, Andrew P. Combs, Artem Shvartsbart |
2021-11-02 |
$33,545,000 |
| 11091484 |
Tricyclic heterocycles as BET protein inhibitors |
James D. Rodgers, Haisheng Wang, Lixin Shao |
2021-08-17 |
$40,819,000 |
| 11091491 |
Heterocyclic compounds as PI3K-y inhibitors |
Artem Shvartsbart, Andrew P. Combs, Lixin Shao, Nikoo Falahatpisheh, Ge Zou +4 more |
2021-08-17 |
$40,819,000 |
| 11078204 |
Heterocyclic derivatives as PI3K inhibitors |
Yanran Ai, Andrew P. Combs, Nikoo Falahatpisheh, Lixin Shao, Artem Shvartsbart |
2021-08-03 |
$119,046,000 |
| 11046658 |
Aminopyrazine derivatives as PI3K-γ inhibitors |
Brent Douty, Yanran Ai, David M. Burns, Andrew P. Combs, Nikoo Falahatpisheh +6 more |
2021-06-29 |
$68,992,000 |
| 10975088 |
Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors |
Andrew W. Buesking, Richard B. Sparks, Andrew P. Combs, Brent Douty, Nikoo Falahatpisheh +5 more |
2021-04-13 |
$77,418,000 |
| 10738057 |
Tertiary alcohols as PI3K-γ inhibitors |
Brent Douty, Andrew W. Buesking, David M. Burns, Andrew P. Combs, Nikoo Falahatpisheh +7 more |
2020-08-11 |
$88,019,000 |
| 10669262 |
Aminopyrazine diol compounds as PI3K-γ inhibitors |
Andrew P. Combs, Nikoo Falahatpisheh, Lixin Shao |
2020-06-02 |
$76,788,000 |
| 10640506 |
Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidines derivatives as JAK inhibitors |
James D. Rodgers, Lixin Shao, Joseph Glenn |
2020-05-05 |
|